All In Biotech

Drug Trial Radar · NCT02014376

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

A Phase 2b, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa

Last checked: Nov 19, 2026Latest source record: Jan 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

48

Actual

Start

Jan 6, 2014

Primary completion

Jun 24, 2014

Study completion Jun 24, 2014

Sponsor

Lead sponsor
Scioderm, Inc.Industry
Sponsor type
Industry
Collaborators
Amicus Therapeutics
First posted
Dec 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).

Conditions

  • Epidermolysis Bullosa

Interventions

  • SD-101 dermal cream (3%)Drug

    SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.

  • SD-101 Dermal Cream (6%)Drug

    SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

  • Vehicle (SD-101 0%)Drug

    A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Documented Complete Closure Of The Target Wound Within 1 Month After Initiation Of TreatmentTime frame: Baseline to 1 Month

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Palo Alto, California

  • Site not named

    Chicago, Illinois

  • Site not named

    St Louis, Missouri

  • Site not named

    Hackensack, New Jersey

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    San Antonio, Texas

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.